Effect of eHealth on AB Use of Children With Acute, Uncomplicated URTIs
Launched by MAX NIEUWDORP · Nov 17, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how helpful two eHealth applications can be for parents of children with common upper respiratory infections, like colds. The main goal is to see if using a self-management app for fever and a decision-making tool for herbal medicine can reduce the need for antibiotics in children. Parents of children aged 0 to 12 who have a fever and certain symptoms, and who have called their doctor but don’t need an in-person visit, might be eligible to participate.
Participants will start by filling out an online questionnaire and then use one of the eHealth apps for ten days. They will also report how their child's symptoms are improving at various points during this time and will complete a follow-up questionnaire at the end. The trial will compare three groups: one using the fever app, another using the herbal medicine tool, and a control group receiving standard advice from their doctor. This study is not yet recruiting but aims to help determine the best ways to manage these common infections without overusing antibiotics.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Having a child aged 0-12 years old
- • Master the Dutch language
- * Having called the GP for their child aged 0-12 years having:
- • Fever (≥38 °C) AND
- * At least one of the following symptoms:
- • Acute cough
- • Sore throat
- • Earache/runny ear
- • Nasal congestion/runny nose
- • Headache
- • Being screened by a triage specialist (GP practice assistant) and not being indicated for a GP/NP/PA visit
- • Not being included in the trial before
- Exclusion Criteria:
- • The current URTI complaints of the child already exist longer than 2 weeks
- • The child who has a URTI
- • is younger than 3 months old
- • has asthma or another chronic or severe illness
- • has a history of pneumonia
- • has a history of complications or hospitalization from a previous URTI
- • has Down Syndrome
- • has a less functioning immune system
- • The parent being very worried
About Max Nieuwdorp
Max Nieuwdorp is a prominent clinical trial sponsor renowned for his innovative research in the field of metabolic diseases, particularly diabetes and obesity. With a strong academic background and extensive experience in translational medicine, Dr. Nieuwdorp leads cutting-edge studies aimed at understanding the complex interplay between metabolism, gut microbiota, and systemic health. His commitment to advancing therapeutic strategies is reflected in a robust portfolio of clinical trials designed to enhance patient outcomes and contribute to the scientific community’s understanding of metabolic disorders. Dr. Nieuwdorp's collaborative approach and dedication to rigorous research make him a key figure in the pursuit of novel treatments in the healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amsterdam, , Netherlands
Patients applied
Trial Officials
Max Nieuwdorp, PhD
Study Director
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported